Quoin Pharmaceuticals Ltd Stock Performance
| QNRX Stock | USD 0.28 0.02 6.67% |
The company holds a Beta of -0.84, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Quoin Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Quoin Pharmaceuticals is likely to outperform the market. At this point, Quoin Pharmaceuticals has a negative expected return of -0.86%. Please make sure to check Quoin Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Quoin Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Quoin Pharmaceuticals Ltd has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:12 | Dividend Date 2019-10-23 | Last Split Date 2023-07-18 |
1 | Decoding Vir Biotechnology Inc A Strategic SWOT Insight | 02/28/2025 |
2 | Cryostat Market to Hit USD 3.69 Billion by 2032 Driven by Advancements in Healthcare and Biotechnology SNS Insider | 03/05/2025 |
3 | Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results | 03/13/2025 |
4 | Hvsen Biotechnology Co., Ltd.s market cap surged CN256m last week, private companies who have a lot riding on the company were rewarded | 03/17/2025 |
5 | Human Augmentation Market to Grow USD 985.13 Billion by 2032, Driven by Advancements in AI, Wearable Technology and Biotechnology SNS Insider | 03/18/2025 |
6 | Acquisition by Langer Dennis of 7652 shares of Quoin Pharmaceuticals at 5.75 subject to Rule 16b-3 | 03/19/2025 |
7 | CBSE Biotechnology Exam Tomorrow, Check Important Questions Here | 03/20/2025 |
8 | A Biotechnology and Bioengineering Design Award Unveils Comprehensive Prize Package for 2024 | 03/21/2025 |
9 | Investor Alert Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit | 03/24/2025 |
| Begin Period Cash Flow | 2.4 M |
Quoin |
Quoin Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 56.00 in Quoin Pharmaceuticals Ltd on December 26, 2024 and sell it today you would lose (28.00) from holding Quoin Pharmaceuticals Ltd or give up 50.0% of portfolio value over 90 days. Quoin Pharmaceuticals Ltd is currently does not generate positive expected returns and assumes 7.5133% risk (volatility on return distribution) over the 90 days horizon. In different words, 67% of stocks are less volatile than Quoin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Quoin Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Quoin Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Quoin Pharmaceuticals Ltd, and traders can use it to determine the average amount a Quoin Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1148
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | QNRX |
Estimated Market Risk
| 7.51 actual daily | 67 67% of assets are less volatile |
Expected Return
| -0.86 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Quoin Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Quoin Pharmaceuticals by adding Quoin Pharmaceuticals to a well-diversified portfolio.
Quoin Pharmaceuticals Fundamentals Growth
Quoin Stock prices reflect investors' perceptions of the future prospects and financial health of Quoin Pharmaceuticals, and Quoin Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Quoin Stock performance.
| Return On Equity | -1.21 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (7.96 M) | ||||
| Shares Outstanding | 20.59 M | ||||
| Price To Book | 0.66 X | ||||
| EBITDA | (9.43 M) | ||||
| Net Income | (8.96 B) | ||||
| Cash And Equivalents | 2.69 M | ||||
| Cash Per Share | 0.56 X | ||||
| Total Debt | 6.5 B | ||||
| Debt To Equity | 0.47 % | ||||
| Current Ratio | 0.96 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (7.86 B) | ||||
| Earnings Per Share | (1.91) X | ||||
| Market Capitalization | 5.79 M | ||||
| Total Asset | 15.71 B | ||||
| Retained Earnings | (55.17 B) | ||||
| Working Capital | 10.75 M | ||||
About Quoin Pharmaceuticals Performance
Evaluating Quoin Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Quoin Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Quoin Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.56) | |
| Return On Capital Employed | (1.26) | (1.32) | |
| Return On Assets | (0.57) | (0.54) | |
| Return On Equity | (0.97) | (1.02) |
Things to note about Quoin Pharmaceuticals performance evaluation
Checking the ongoing alerts about Quoin Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Quoin Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Quoin Pharmaceuticals generated a negative expected return over the last 90 days | |
| Quoin Pharmaceuticals has high historical volatility and very poor performance | |
| Quoin Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Quoin Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Quoin Pharmaceuticals Ltd currently holds 6.5 B in liabilities with Debt to Equity (D/E) ratio of 0.47, which is about average as compared to similar companies. Quoin Pharmaceuticals has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Quoin Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (8.96 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quoin Pharmaceuticals Ltd currently holds about 2.69 M in cash with (7.86 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Investor Alert Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit |
- Analyzing Quoin Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Quoin Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Quoin Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Quoin Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Quoin Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Quoin Pharmaceuticals' stock. These opinions can provide insight into Quoin Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Quoin Stock Analysis
When running Quoin Pharmaceuticals' price analysis, check to measure Quoin Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quoin Pharmaceuticals is operating at the current time. Most of Quoin Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Quoin Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quoin Pharmaceuticals' price. Additionally, you may evaluate how the addition of Quoin Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.